Ž
. Effects of gamma-vinyl-GABA GVG , an antiepileptic drug that inhibits GABA transaminase and increases extracellular GABA concentrations in the brain, were investigated on Ž . Ž the morphine abstinence syndrome AS in male Wistar rats. Two morphine pellets 75 mg . morphine base in each were implanted subcutaneously on the back of the rats. Seventy-two Ž y1 . hours after the morphine implantation, naloxone NL, 2 mg kg was injected intraperi-Ž . toneally i.p. to induce precipitated morphine AS. GVG was administered at the doses of y1 Ž . y 1 Ž . 250 mg kg n s 11 and 500 mg kg n s 11 i.p. 24 h prior to AS and at the dose of 500 y1 Ž . mg kg n s 13 i.p. 6 h prior to AS. Immediately after NL injections, rats were observed Ž for 5 min and AS signs jumping, teeth chattering, wet dog shake, diarrhoea, ptosis and . defecation were assessed. The behavioural signs of GVG-treated rats were compared with Ž . the control groups n s 10 during the AS. Jumping, wet dog shake, teeth chattering were found to be significantly increased in all of the GVG-treated groups. Ptosis was found to have increased in only 500 mg kg y1 GVG groups. GVG potentiated the severity of morphine AS signs. GVG does not seem to have any therapeutic potential for treatment of morphine abstinence unlike some other drugs that enhance GABAergic transmission.
INTRODUCTION
Chronic administration of opiates, such as morphine, produces tolerance and dependence, limiting w x their clinical use 1, 2 . Although the mechanisms underlying the development of physical dependence Ž . and the expression of abstinence syndrome AS are not clear, previous reports suggest that multiple receptors and neurotransmitter systems may be involved in the development of opiate dependence w x 1᎐3 . It has recently been shown that excitatory Ž . amino acids EAA and activation of N-methyl-D-Ž . aspartate NMDA receptors play an important role in the development of morphine physical depen-Ž . dence MPD and in the expression of naloxone Ž . NL precipitated morphine withdrawal syndrome w x 4᎐9 . NMDA receptor antagonists blocked NL prew x cipitated morphine AS 4᎐9 . It has also been reported that acute morphine administration is prow x convulsant, as well as anticonvulsant 10 . It has been hypothesized that morphine abstinence syndrome is an excessive excitation of various regions of w x the central nervous system 7, 8 . Although the role of EAA and NMDA receptors has been defined, the subtle mechanisms of inhibitory systems in the development and expression of morphine AS has not yet been clearly elucidated.
Ž . Gamma amino butyric acid GABA is the major inhibitory neurotransmitter in the central nervous system released from GABAergic interneurons and many studies have demonstrated the importance of GABAergic transmission in epilepsy or other neurow x logical disorders 11 . It is known that GABAergic transmission inhibits the excitation of the neurons in various parts of the central nervous system. It has been reported that benzodiazepine pretreatment, that enhances the GABAergic transmission, supw x presses morphine withdrawal signs 12 . It is also reported that the GABAergic system plays an important role in the development of MPD andror morphine tolerance, however, a clear picture of the role of GABAergic system has not yet been exw x plained 13, 14 . Hence it is important to elucidate the role of excitatory and inhibitory systems in the mechanism of the development of MPD.
Ž . Vigabatrin gamma-vinyl-GABA, GVG is a potent antiepileptic drug that inhibits GABA transaminase activity and increases extracellular GABA levels in many regions of the mammalian brain up to w x tenfolds 15᎐17 . GVG antagonizes seizures in variw x ous models of epilepsy 18᎐21 and has an anxiolytic w x effect 22 . GVG is expected to suppress the excitation of the central nervous system and the signs of NL precipitated AS in the rodent model of MPD. If this were the case, GVG could be a drug of choice in the treatment of morphine withdrawal syndrome, w x like diazepam 23 . The present study was designed to elucidate whether GVG had an inhibitory effect on the signs of MPD.
MATERIAL AND METHODS

Animals and laboratory
Ž . Male Wistar inbred rats 250᎐300 g , that were Ž . Ž kept in a temperature 22 " 2ЊC and humidity 62 " . 4% controlled room in which a 12-h lightrdark cycle was maintained. They were fed with a standard Ž . regimen lab chow ad libitum.
Drugs
Vigabatrin was a generous gift from the Merrill-Ž . Dow Institute Strasbourg, France . Naloxone and Ž morphine were purchased from Sigma St. Louis, . MO , Verenigde Pharmaceutische Fabrieken B.V. Ž . Holland , respectively. Vigabatrin and naloxone were dissolved in saline and injected into rats i.p., an equal amount of saline was injected into the control groups.
Methods
Ž .
Two pellets containing 75 mg morphine base M Ž . Ž . total 150 mg were subcutaneously SC implanted on the back of the rats lightly anaesthetised with w ether to induce MPD, as previously described 8, x 24᎐26 . Abstinence syndrome was precipitated by Ž y1 . the injection of NL 2 mg kg i.p. 72 h after pellet implantation. The rats were assigned into seven groups at random. Ž The experimental groups were as follows sum-. marised in Table I : Ž . 1. No treatment group n s 8 . The rats in this group were implanted with placebo pellets which did not contain morphine, they only Ž y1 . received NL 2 mg kg i.p. 72 h after the pellet implantation and observed.
Ž . 2. The group that received only GVG n s 8 .
This was a control group for GVG. The rats in Ž this group were injected with GVG 500 mg y1 . kg i.p. and observed 24 h later. Ž . 3. The group that received GVG and NL n s 8 .
The rats in this group were injected with Ž y1 . GVG 500 mg kg i.p. and 24 h later, they Ž y1 . were injected with NL 2 mg kg i.p. and observed.
Ž . 4. Control group n s 10 . These rats were im-Ž planted with two morphine pellets MP, each . containing 75 mg morphine base . Seventy-two hours after the implantation of MP, AS was Ž precipitated by the injection of NL 2 mg y1 . kg i.p. y1 Ž . 5. GVG-250 mg kg -24 h group n s 11 . These rats were implanted with two MP. Twenty-four hours before the precipitated morphine AS, Ž y1 . they were injected with GVG 250 mg kg i.p. Twenty-four hours was chosen because after the injection of GVG, GABA levels w x peaked at the 24th hour 15 . Twenty-four hours after GVG administration, the AS was 
. GVG-500 mg kg -6 h group n s 13 . These rats were implanted with two MP. Six hours Ž y1 . before the NL 2 mg kg induced precipi-Ž tated AS, they were injected with GVG 500 y1 . mg kg i.p. y1 Ž . 7. GVG-500 mg kg -24 h n s 11 . These rats were implanted with two MP. Twenty-four hours before the NL injection, they were in-Ž y1 . jected with GVG 500 mg kg i.p. Seventytwo hours after MP implantation, they were Ž y1 . injected with NL 2 mg kg i.p. to induce the AS and were observed. In the MP implanted groups, after the injection of NL, the rats were immediately placed in a metal Ž . cage base area, 20 = 22 cm; height, 20 cm and observed for 10 min by an experimenter blind to group identification. The withdrawal signs of jumping, wet dog shake, teeth chattering, diarrhoea, defew x cation and ptosis were counted or rated 8, 24᎐26 . During this observation period the number of jumps, wet dog shakes and defecations were counted. Teeth chattering and, diarrhoea or ptosis were rated 1᎐10 and 1, 2, 3, respectively according to their severity as w x reported before 8, 24᎐26 . General ethical considerations on the maintenance of and experimentation on the animals were obeyed throughout this study.
The results were analysed by Kruskall᎐Wallis multiple comparison test, followed by Mann᎐Whit-ney U-test. The groups were compared with the control group and P-0.05 was considered to be statistically significant.
RESULTS
Ž
. The mean values "SE and their statistical evaluation of the AS signs of groups 4᎐7 during the first 10 min immediately after 2 mg kg y1 of NL administration are shown in Figs. 1 Fig. 2 A,B . Ptosis was significantly different than the control y1 w group in 500 mg kg GVG groups H s 6.36,
x Ž . P-0.01 Fig. 2 . GVG increased the severity of NL precipitated AS in morphine-dependent rats.
DISCUSSION
It was expected that GVG, an antiepileptic drug that increases extracellular levels of GABA in many parts w x of the brain 15, 17 , would suppress the signs of morphine AS, however, we observed an opposite result.
Excitatory and inhibitory amino acids play an important role in the development and expression of w x MPD 5᎐9 . There is an altered release of excitatory w x and inhibitory neurotransmitters, e.g. glutamate 27 w x andror GABA 14, 28 during the development of MPD. GABA levels are decreased in the ventral w x w x tegmental area 29 , midbrain 30 and cortical slices w x 31 following morphine treatment. While GABA levels are found to be decreased, acetylcholine was reported to be increased in the cortex during morw x phine withdrawal 32 . Chronic morphine administration enhances GABA receptor function and in-A creases the benzodiazepine binding in the cortex w x Ž 28 . Administration of diazepam 1, 2 and 4 mg y1 . kg injected 1 h before the NL challenge increased the number of jumping and wet dog shakes w x and the severity of abstinence syndrome 33 . Benzodiazepine pretreatment has also been reported to w x suppress the withdrawal 12 suggesting that a possible decrease of GABAergic inhibition may underlie MPD. Pentobarbital, that enhances GABAergic transmission, antagonize the antinociceptive effects w x of morphine 34 .
During withdrawal, if GABA levels are decreased, the most important question is whether a reduction in GABA contributes to AS or results from it. When we administered GVG to elevate GABA levels in the brain prior to precipitation of AS by NL, we found unexpected results, similar to the findings of w x Baldino et al. 33 .
Our findings seem to be in direct contradiction to w x that which Contreras et al. have reported 35 . They . Ž . Ž . Ž . wet dog shake P-0.05 . C Effect on the severity of teeth chattering 1᎐10 scale P-0.05 . Observation was made for y1 Ž y1 . 10 min after the naloxone injection; 250-24 h stands for 250 mg kg GVG injection 24 h before naloxone NL, 2 mg kg precipitated abstinence syndrome; 500-6 h stands for 500 mg kg y1 GVG injection 6 h before NL injection; 500-24 h stands for 500 mg kg y1 GVG injection 24 h before NL injection.
found that GVG induced a decrease in the severity of the AS in mice, while another GABA-transaminase inhibitor ␥-acetylenic GABA, in contrast, induced convulsions in the morphine-dependent mice. The rating and scoring of the signs of AS in this study was very different from our conventional w x way of scoring 7, 8, 24᎐26 ; it was a protectedrunprotected scale which is more difficult to assess the withdrawal. The findings of Contreras et al. is very hard to compare with our or other researchers' studies; discrepancies between these results may be related to different species of animals, observation intervals, doses, routes of injection or methods of scoring AS.
These unexpected effects of GVG on NL precipitated AS may be explained by three mechanisms. First, by the untoward effects of extracellular GABA increase; second, by a possible enhanced glutamatergic activity induced by GVG andror GABA increase; third, by a possible direct proconvulsant effect of GABA to specific areas like, the superior w x colliculus 20 . Normally, if there is an excessive excitation of neurons in some specific regions of the brain during AS, then the enhancement of GABAergic transmission would be expected to suppress it. However, an increase in the extracellular GABA levels may not always induce an overall increase in the GABA mediated inhibition, because an extra-A .
. cellularly increased GABA level may not always enhance the GABA function in some GABAergic synapses. In a microdialysis study we found that increased extracellular GABA levels, even in subsw x tantia nigra 18 , did not antagonize pentylenetetraw x zol induced tonic᎐clonic seizures 17 . Jackson et al. w x Ž 36 also found that GVG in 250᎐500 M concen-. trations induced a loss of paired pulse inhibition in the CA1 region of rat hippocampal slices, without having any specific binding or antagonistic effects to GABA receptor. In another study, GVG caused a A Ž loss of paired pulse inhibition at 15-ms interpulse . interval in the dentate gyrus of the rat hippocampus in¨i¨o and in¨itro; this effect was blocked by GABA antagonists 2-OH-saclofen and CGP 35348 B w x 37 . These paradoxical effects of GVG may be attributed to the presynaptic inhibition of GABA release at the GABAergic synapses by the excessive stimulation of presynaptically located GABA au-B toreceptors. Thus, GVG, indirectly, may be reducing the synaptically released, active GABA at some parts of the brain, instead of increasing the inhibition. w x Although GVG is a potent antiepileptic drug 16 , and has reduced seizure frequency by approximately w x 50᎐60% 38, 39 , it has also been reported to exacerw x bate primary generalized seizures 40 and precipiw x tate status epilepticus 41 , possibly by means of similar mechanism mentioned above.
A second explanation of these effects may be through an interaction with glutamatergic system. GVG inhibits glutamic acid decarboxylase, an enzyme that converts glutamate, an excitatory amino w x acid, to GABA 16 . Increased extracellular GABA levels may also be limiting the rate of this enzyme, resulting in increased glutamate, which is the precursor of GABA, in the presynaptic pools. As rew x ported before 7, 8 combined with the possible altered release of glutamate modulated by the w x chronic administration of morphine 3, 7, 8, 27 , an acute excessive release of this glutamate pool may induce a severe AS.
A third explanation may be the possible proconvulsant andror excitatory effect of increased GABA levels at some specific areas of the brain, like superior colliculus, where antagonism of the GABAergic w x system is inhibitory and anticonvulsant 42 , may w prevail over the inhibitory GABAergic system 11, x 20, 42 . Another important point may be a possible interaction between the increased extracellular Ž . GABA levels or GVG itself with morphine during the development of MPD, however, there are no reports explaining such an interaction. Further research to elucidate the mechanism of how morphine AS becomes more severe when extracellular GABA levels in the brain is increased may give important clues about the development of morphine AS and the interaction between the opioid and GABAergic system. GVG does not seem to have any therapeutic potential for treatment of morphine abstinence in contrast to other drugs that enhance GABAergic transmission, like benzodiazepines.
